Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Open in API
Filings indexed 383 across all filing types
Latest filing 2024-05-09 Earnings Release
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2024, by Amylyx Pharmaceuticals, Inc. It announces the issuance of a press release containing financial results for the fiscal quarter ended March 31, 2024. The document itself does not contain detailed financial statements or substantive financial data but rather furnishes the press release as an exhibit. The length is 3490 characters, which is relatively short and consistent with an announcement rather than a full report. The document explicitly states that the information is not "filed" for certain regulatory purposes and is a current report announcing the results. This matches the characteristics of an Earnings Release (ER) filing, which is the initial announcement of quarterly financial results with key highlights only, typically disseminated via press release and filed on Form 8-K. Therefore, the correct classification is Earnings Release (ER).
2024-05-09 English
ARS
Annual Report
2024-04-24 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed with the SEC. It includes information about the upcoming annual stockholder meeting, voting instructions, proposals to be voted on, and board recommendations. The document explicitly states it is a "Definitive Additional Materials" filing related to the proxy statement for the annual meeting. It does not contain the full proxy statement itself but additional materials related to it. According to the filing definitions, proxy solicitation and information statements, including definitive proxy statements and related materials, fall under the category "Proxy Solicitation & Information Statement" (PSI). The document is not an annual report, earnings release, or other financial report but a proxy-related filing. Therefore, the correct classification is PSI with high confidence.
2024-04-24 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-24 English
4
Director's Dealing
2024-04-19 English
4
Director's Dealing
2024-04-19 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.